Challenges for Drug Repurposing in the COVID-19 Pandemic Era

Frontiers in Pharmacology

Janet Sultana¹  Gianluca Trifirò¹  Salvatore Crisafulli¹  Saad Shakir³  Elizabeth Lynn³  Flic Gabbay⁴ 

[1] Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy;Drug Safety Research Unit, Southampton, United Kingdom;School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, United Kingdom;TranScrip, Reading, United Kingdom;

关键词: drug repurposing;    drug repositioning;    COVID-19;    pandemic;    coronavirus;   

DOI  :  10.3389/fphar.2020.588654

来源: DOAJ

【 摘 要 】

The coronavirus disease (COVID-19) pandemic has affected an estimated 16 million persons and caused 0.6 million deaths worldwide by September 2020. The pandemic has led to a rush to repurpose existing drugs, although the underlying evidence base is of variable quality. The improving knowledge of the virology and clinical presentation of COVID-19 is leading to a broadening pool of potential pharmacological targets. The aim of this review is to describe regulatory and pharmacological aspects of drug repurposing and to identify drugs proposed for repurposing in COVID-19 based on registered clinical trials, discussing the evidence to support their use in the treatment of this disease. The challenges of the correct interpretation of existing pre-clinical/clinical evidence as well as the generation of new evidence concerning drug repurposing in COVID-19 will also be discussed.Clinical Trial Registration:https://clinicaltrials.gov, identifier NCT04321174, NCT04342663, NCT04280705, NCT04244591, NCT04359329, NCT04348695, NCT04304313, NCT043505931

【 授权许可】

Unknown